Lynn Seely

Lynn Seely is currently the President, Chief Executive Officer & Director at Lyell Immunopharma, Inc. since 2022.
She is also an Independent Director at Blueprint Medicines Corp.
since 2016.
Previously, she served as the Chief Executive Officer of Myovant Sciences, Inc. from 2019 to 2020 and as the President, Chief Executive Officer & Director of Myovant Sciences Ltd.
from 2016 to 2021.
Dr. Seely also held positions at Chiron Corp.
as an Associate Director-Clinical Development from 1996 to 2000, at Orion Acquisition Corp.
II as the Chief Medical Officer in 2005, at Anesiva, Inc. as the Vice President-Clinical Development from 2002 to 2005, at Pro-Duct Health, Inc. as the Vice President-Clinical Development from 2000 to 2001, and at the University of California San Diego as a Faculty Member from 1992 to 1996.
She was also the Chief Medical Officer & Senior Vice President at Medivation LLC (California) from 2009 to 2015, the Vice President-Clinical Development at Cytyc Health Corp.
from 2001 to 2002, and the Vice President-Clinical Development at Corgentech, Inc. in 2005.
Dr. Seely's education includes an undergraduate degree from the University of Oklahoma in 1981 and a doctorate degree from the University of Oklahoma College of Medicine in 1985.